SEOVF
Sernova Biotherapeutics Inc
Set alert
0.08 USD 0.00 0.00%
0.0759 Day range 0.0759
0.06 52-week range 0.14
- YTD
- -11.11%
- 1 year
- -27.27%
- Open
- 0.0759
- Prev close
- 0.08
- Mkt cap
- 30.21M
- Vol
- 458
- Avg vol
- 83.70K
- EPS
- 0.01
- P/E
- 8.00
More statistics
- Low
- 0.0759
- High
- 0.0759
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2025 | Oct 1, 2024 | 0.00 | -0.01 | — | — |
| Sep 16, 2024 | Jul 1, 2024 | 0.00 | -0.01 | — | — |
| Jun 14, 2024 | Apr 1, 2024 | 0.00 | -0.02 | — | — |
| Mar 18, 2024 | Jan 1, 2024 | 0.00 | -0.02 | — | — |
| Jan 29, 2024 | Oct 1, 2023 | 0.00 | -0.03 | — | — |
| Sep 13, 2023 | Jul 1, 2023 | 0.00 | -0.02 | — | — |
News
- Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
- Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference
- Sernova Biotherapeutics Announces Closing of Recently Approved Financings
- Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
- Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
- Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
- Sernova Biotherapeutics Announces Warrant Amendments
- Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
- Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
- Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
Your note
Sign in to keep a note on SEOVF — it syncs with the Stock Master app.